Description: Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s.
Home Page: www.athira.com
ATHA Technical Analysis
18706 North Creek Parkway
Bothell,
WA
98011
United States
Phone:
425 620 8501
Officers
| Name | Title |
|---|---|
| Dr. Mark J. Litton M.B.A., MBA, Ph.D. | Pres, CEO & Director |
| Ms. Rachel P. Lenington M.B.A. | Chief Operating Officer |
| Mr. Mark F. Worthington J.D. | Gen. Counsel & Corp. Sec. |
| Ms. Glenna K. Mileson | Chief Financial Officer |
| Mr. Robert Renninger | Director of Accounting & Reporting |
| Ms. Julie Rathbun | Head of Investor Relations |
| Dr. Kevin Church Ph.D. | Exec. VP of Research |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4731 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 34 |